Chris Bahl is the President, CEO and Founder of AI Proteins, a Boston-based biotech company at the forefront of re-imagining protein-based medicines through innovative design and development of miniproteins. Leveraging synthetic biology, robotics and automation, and artificial intelligence, AI Proteins creates miniproteins with ideal therapeutic properties. Chris' work focuses on advancing the company's pipeline in oncology and exploring partnerships in other therapeutic areas. Prior to founding AI Proteins, Chris was one of the founding faculty members at the Institute for Protein Innovation in Boston, with co-appointments at Boston Children's Hospital and Harvard Medical School. Chris pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with Nobel Laureate David Baker at the Institute for Protein Design in Seattle. Chris is dedicated to spreading knowledge in computational protein design through initiatives that he founded such as the Boston Protein Design and Modeling Club and The Latin American Workshop on Artificial Intelligence for Protein Design. Chris sits on the Executive Council of The Protein Society, and he serves as a Scientific Advisor for Applied Photophysics and BioLoomics.
Areas of Expertise
Biotech entrepreneurship, biochemistry, protein design, protein engineering, structural biology, synthetic biology
